Subscribe
Share
Share
Embed
Thinking in Psychiatry is an Academy by Psych Scene podcast featuring short, high-signal audio episodes you can listen to on the go. Each week we break down emerging evidence, evolving clinical frameworks, and complex cases across the lifespan – from psychopharmacology and neurobiology to formulation, systems thinking, and metabolic and sleep psychiatry. Designed for busy clinicians, every episode is grounded in evidence, reviewed by faculty, and focused on one question: how can we practise better psychiatry, starting today?
Welcome to Thinking in Psychiatry, a podcast from the Academy by PsychScene where we delve into the latest research, present evidence based insights, and support informed clinical decision making for busy healthcare professionals.
Speaker 2:We are your hosts, AI research fellows connected with the Academy by PsychSene. All material discussed here is reviewed by our clinical faculty.
Speaker 1:Today, we address an important question that remains at the core of Alzheimer's research: why is Alzheimer's disease more prevalent among women? This discussion is based on a 2025 JAMA article by Rita Rubin.
Speaker 2:An excellent topic indeed. Historically, the assumption was that longevity accounts for this trend, as women tend to outlive men. However, current research indicates a considerably more intricate narrative.
Speaker 1:Indeed, while longevity is a contributing factor, emerging evidence elucidates multifaceted influences encompassing biological, hormonal, genetic, immunological pathways, and socio environmental considerations. This knowledge reshapes how we assess, diagnose, and approach therapeutic strategies for individuals.
Speaker 2:Exactly. It's not just about knowing the statistics, it's about using them in practice, applying a thorough and patient centered approach to risk assessment and intervention. Let's explore the implications further.
Speaker 1:Starting with clinical outcomes, data from a substantial U. S. Medicare cohort involving five point seven million elder adults diagnosed with dementia revealed that men had a twenty four percent mortality rate within the first year post diagnosis compared to women.
Speaker 2:So, men are dying sooner after diagnosis, but women are living longer with dementia, often diagnosed at later stages due to subtler manifestations during early memory Crucially concerning, isn't it?
Speaker 1:Exactly! Women's adaptive abilities in early cognitive tests conceal the impairment, delaying recognition until the disease progresses significantly. Such dynamics demand early and improved diagnostic approaches.
Speaker 2:Neurobiologically, tau protein pathology exhibits distinct gender specific progression, considering its implications could substantially influence clinical strategies.
Speaker 1:Research suggests that once amyloid plaques appear, women exhibit more rapid accumulation of tau proteins, which correlates with accelerated cognitive decline. So, it's not that women get more Alzheimer's, it's that the disease behaves differently in female brains. This aligns with autopsy data. Cognition and tau burden correlate more tightly in women.
Speaker 2:This variation prompts consideration about therapeutic approaches, particularly regarding emerging anti amyloid treatments and their differential efficacies across genders.
Speaker 1:Interesting clinical twist: Early analyses from lacanemab trials show women may experience smaller treatment effects than men. Still preliminary, but worth watching. Trials weren't powered to answer sex difference questions, which is part of the problem. Historically, sex stratified reporting has been inconsistent. Donanemab may be more balanced, possibly due to lower baseline tau in trial participants.
Speaker 1:Again, highlights how tau biology matters. Future trials with patient sex stratified analyses are essential to refine our understanding.
Speaker 2:Let's talk hormones. The estrogen drop at menopause appears to remove several neuroprotective functions: anti inflammatory effects, synaptic plasticity, neurogenesis support, which introduces nuanced challenges in women's Alzheimer's risk profiles,
Speaker 1:And observational studies suggest estradiol therapy earlier in menopause may support memory, but the WHIMS study warned about increased dementia risk when started later in life. So, timing, formulation, and individual risk matter. It's not a blanket recommendation, but hormone history belongs in cognitive risk assessment.
Speaker 2:Indeed, hormonal supplementation requires a personalized assessment. A comprehensive health history including endocrine transitions could inform risk management strategies.
Speaker 1:Moreover, genetic susceptibility factors further complicate this landscape. For instance, the APOE E4 allele disproportionately elevates Alzheimer's risk in women, highlighting the necessity for gender informed genetic counseling.
Speaker 2:Absolutely, and there's emerging research into X chromosome gene escape. Women have two X chromosomes, and some genes evade inactivation. That could modify disease susceptibility and immune response early science, but it may point towards future therapeutic targets.
Speaker 1:Let's not forget modifiable factors. Women, in population studies, show higher rates of depression, inactivity, social isolation, sleep disturbance, diabetes, and lower education access, all linked to cognitive decline. Men, meanwhile, show higher hearing loss and alcohol misuse. But importantly, the impact of risk factors differs by sex, so risk reduction needs a sex specific approach.
Speaker 2:So, stepping back, what's actually driving these sex differences in Alzheimer's? At a mechanistic level, several themes emerge: women show faster tau spread once amyloid is present, and their symptoms correlate more closely with the underlying pathology. The hormonal shift that menopause, particularly estrogen withdraw, appears to shape microglia behavior, synaptic resilience, and inflammatory tone. Add to that the greater impact of the ApoE4 genotype in women and emerging evidence around immune genetic interactions on the X chromosome, and we begin to see a biologically coherent pattern.
Speaker 1:Exactly! It reminds us that Alzheimer's isn't just age plus amyloid. It's a hormone, immune, genetic, network disorder, and sex biology shapes that landscape.
Speaker 2:So, clinically, how do we translate this?
Speaker 1:We shift how we assess and how we intervene. First, take a genuinely sex specific prevention history. Menopause timing, pregnancies, autoimmune conditions, and cancer therapies all matter. Second, be cautious early in the diagnostic process. Women can compensate cognitively for longer, so surface level cognitive testing may not reflect underlying disease burden.
Speaker 1:Third, prioritize midlife risk modification: sleep, vascular health, metabolic risk, mood, and social engagement. And finally, when patients are receiving disease modifying therapies, monitor outcomes closely and advocate for sex stratified data. In other words, individualized medicine with a sex lens, not a one size fits all model.
Speaker 2:A few pearls before we close: Women may decline more quickly once pathology takes hold. Tau biology may be the real differentiator, not amyloid alone. And the period around midlife, not late life, is where neuroprotection likely has the greatest value.
Speaker 1:And let's not lose sight of context social determinants sit right along synapses in shaping outcomes.
Speaker 2:That brings us to the end of today's discussion. Thanks for listening. You can find links to the papers and related Academy modules on your dashboard, including our comprehensive Alzheimer's disease diagnosis and management course, where we dive deeper into clinical recognition, biomarkers, therapeutics, and practical management approaches.
Speaker 1:Stay tuned for our next episode, and we'll see you then.